Prognosis according to the timing of recurrence in breast cancer

Lee, Young Joo; Jung, Seung Pil; Bae, Jeoung Won; Yang, Sun Moon; You, Ji Young; Bae, Soo Youn

doi:10.4174/astr.2023.104.1.1

Cited by 8 publications

(2 citation statements)

References 28 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HR+/HER2-luminal type breast cancer is often associated with late recurrence [24]. Survival analysis in the present study found that tChoi was associated with a signi cant difference in 10-year DFS, particularly late recurrence, in patients with HR+/HER2-tumors.…”

Section: Discussionsupporting

confidence: 51%

Prognostic significance of total choline on in-vivo proton MR spectroscopy for 10-year survival in patients with: hormone receptor-positive, HER2-negative early breast cancer

Kim,

Park,

Chun

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose In-vivo proton magnetic resonance spectroscopy (MRS) is a non-invasive method of analyzing choline metabolism that has been used to predict breast cancer prognosis. A strong choline peak may be a surrogate for aggressive tumor biology but its clinical relevance is unclear. The present study assessed whether total choline(tCho), as measured by proton MRS, can predict survival in patients with hormone receptor(HR)-positive, HER2-negative early breast cancer. Methods The study cohort included 560 breast cancer patients who underwent diagnostic single-voxel proton MRS (3.0T scanner) prior to first-line surgery from March 2011 to July 2014. The relationships between tCho compound peak integral (tChoi) values and biologic subtypes were analyzed, as were the effects of tChoi on 10-year disease-free survival (DFS) and overall survival (OS). The clinical significance of tChoi was also analyzed using Harrell's C-index. Results Of the 560 patients included in this study, 261 had HR+/HER2- breast cancer. Mean tChoi differed among patients with HR+/HER2- (15.5), triple negative (20.6), HR+/HER2+ (17.1), and HR-/HER2+ (15.0) breast cancer (p = 0.07). 10-year DFS differed significantly between HR+/HER2- with tChoi < 15 and ≥ 15 (p = 0.017), with differences differing significantly for late (5–10 years; p = 0.02) but not early (0–5 years; p = 0.323) recurrence. Cox regression analysis showed that tChoi was significantly predictive of 10-year DFS (p = 0.046, OR 2.69) and tended to be predictive of late recurrence (HR 4.36, p = 0.066). Harrell’s C-index showed that the Ki-67 index (AUC = 0.597) and lymphovascular invasion (AUC = 0.545) were also predictive of survival, with the addition of normalized tChoi improving the AUC to 0.622 (p = 0.014), indicating better predictive power. Conclusion A tChoi determined by in vivo MRS was predictive of prognosis in patients with HR+/HER2- early breast cancer. This parameter may serve as a valuable, non-invasive tool to predict prognosis when combined with other known prognostic factors.

show abstract

Section: Discussionsupporting

confidence: 51%

Prognostic significance of total choline on in-vivo proton MR spectroscopy for 10-year survival in patients with: hormone receptor-positive, HER2-negative early breast cancer

Kim,

Park,

Chun

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…A range of techniques, such as clinicopathological variables and multigene assays, are employed to evaluate the late recurrence of hormone receptor-positive breast cancer [ 8 9 10 ]. It is needed to identify patients at risk of late recurrence of breast cancer and establish treatment strategies such as extended endocrine therapy.…”

Section: Introductionmentioning

confidence: 99%

Prognostic influences of B-cell lymphoma 2–positive expression on late recurrence in breast cancer

Kim¹,

Eom²,

Choi³

2023

Ann Surg Treat Res

View full text Add to dashboard Cite

Purpose B-cell lymphoma 2 (BCL2) has an antiapoptotic role, however, has resulted in it being a powerful favorable prognostic factor in breast cancer. Several studies revealed BCL2 is strongly associated with a lower rate of early recurrence after initial treatment in breast cancer patients, but study of a prolonged effect after 5 years is lacking. We investigated BCL2 as a prognostic factor in breast cancer in comparison to early and late recurrence. Methods We retrieved data from 2,198 patients with primary breast cancer who underwent surgical treatment and adjuvant treatment at the breast cancer center between 2005 and 2015. Each molecular subtype was classified, and Ki-67 and BCL2 were also assessed by immunohistochemistry. BCL2 and the association between molecular subtypes were assessed in early and late recurrences, respectively. Five-year postrecurrence survival and BCL2 were also assessed. Results The BCL2-positive group was associated with favorable clinicopathologic characteristics. The time to recurrence was significantly longer in the BCL2-positive group (P = 0.035). Late recurrence after 5 years was higher in the BCL2-positive group (P = 0.029). In multivariate survival analysis, tumor size and BCL2-positive expression were the only independent prognostic factors for late recurrence (P = 0.004). In the patients with recurrence, 5-year postrecurrence survival was significantly higher in the BCL2-positive group (P < 0.001). Conclusion Our result showed that prognosis was better in BCL2-positive patients compared to BCL2-negative patients at late recurrence. We suggested that BCL2 expression could be used as a marker to help determine additional adjuvant therapy or extended hormone therapy in hormone-dependent breast cancer.

show abstract

Influence of tumor microenvironment on the different breast cancer subtypes and applied therapies

Ferreira Almeida,

Correia-da-Silva,

Teixeira

et al. 2024

Biochemical Pharmacology

View full text Add to dashboard Cite

Prognosis according to the timing of recurrence in breast cancer

Cited by 8 publications

References 28 publications

Prognostic significance of total choline on in-vivo proton MR spectroscopy for 10-year survival in patients with: hormone receptor-positive, HER2-negative early breast cancer

Prognostic significance of total choline on in-vivo proton MR spectroscopy for 10-year survival in patients with: hormone receptor-positive, HER2-negative early breast cancer

Prognostic influences of B-cell lymphoma 2–positive expression on late recurrence in breast cancer

Influence of tumor microenvironment on the different breast cancer subtypes and applied therapies

Contact Info

Product

Resources

About